

## **AMENDMENTS TO THE SPECIFICATION**

Please amend paragraph [0043] of the published application as follows:

- - Another currently preferred embodiment of the present invention provides a molecule herein denoted MSPRO12 comprising a variable light chain (V<sub>L</sub>) having SEQ ID NO:[94] 87 and a variable heavy chain (V<sub>H</sub>) having amino acid SEQ ID NO:[105] 98 and the corresponding isolated nucleic acid molecules comprising polynucleotide sequences having SEQ ID NO:[75] 68 and SEQ ID NO:[89] 82, respectively. - -

Please amend paragraph [0044] of the published application as follows:

- - Another currently preferred embodiment of the present invention provides a molecule herein denoted MSPRO2 comprising a variable light chain (V<sub>L</sub>) having SEQ ID NO:[92] 85 and a variable heavy chain (V<sub>H</sub>) having SEQ ID NO:[103] 96 and the corresponding isolated nucleic acid molecules comprising polynucleotide sequences having SEQ ID NO:[74] 67 and SEQ ID NO:[84] 77. - -

Please amend paragraph [0045] of the published application as follows:

- - A currently most preferred embodiment of the present invention provides a molecule, herein denoted MSPRO59, comprising a variable light chain (V<sub>L</sub>) having SEQ ID NO:[102] 95 and a variable heavy chain (V<sub>H</sub>) having SEQ ID NO:[113] 106 having the corresponding isolated nucleic acid molecules comprising polynucleotide sequences having SEQ ID NO:[76] 69 and SEQ ID NO:[91] 84, respectively. - -

Please amend paragraph [0047] of the published application as follows:

- - In one embodiment the present invention provides a molecule which binds FGFR3 and blocks ligand-dependent activation of the receptor, comprising V<sub>H</sub>-CDR3 and V<sub>L</sub>-CDR3 regions having SEQ ID NO:20 and SEQ ID NO:21, respectively and the corresponding polynucleotide sequence having SEQ ID NO:44 and SEQ ID NO:45, respectively. In another embodiment the present invention provides a molecule comprising a variable light chain (V<sub>L</sub>) having SEQ ID NO:[99] 92 and a variable heavy chain (V<sub>H</sub>) having SEQ ID NO:[110] 103, having the corresponding isolated nucleic acid molecules comprising polynucleotide sequences having SEQ ID NO:[65] 58 and SEQ ID NO:[87] 80, respectively. - -

Please amend paragraph [0049] of the published application as follows:

- - Additional embodiments of the present invention provide molecules having an antigen binding domain comprising a V<sub>L</sub> region and a V<sub>H</sub> region, respectively, selected from SEQ ID NO: [[93]] 86 and SEQ ID NO: [[104]] 97; SEQ ID NO: [[95]] 88 and SEQ ID NO: [[106]] 99; SEQ ID NO: [[96]] 89 and SEQ ID NO: [[107]] 100; SEQ ID NO: [[97]] 90 and SEQ ID NO: [[108]] 101; SEQ ID NO: [[98]] 91 and SEQ ID NO: [[109]] 102; SEQ ID NO: [[99]] 92 and SEQ ID NO: [[110]] 103; and SEQ ID NO: [[101]] 94 and SEQ ID NO: [[112]] 105 and the corresponding isolated nucleic acid molecules comprising polynucleotide sequences having SEQ ID NO: [[70]] 63 and SEQ ID NO: [[85]] 78; SEQ ID NO: [[67]] 60 and SEQ ID NO: [[78]] 71; SEQ ID NO: [[64]] 57 and SEQ ID NO: [[79]] 72; SEQ ID NO: [[71]] 64 and SEQ ID NO: [[86]] 79; SEQ ID NO: [[62]] 55 and SEQ ID NO: [[80]] 73; SEQ ID NO: [[65]] 58 and SEQ ID NO: [[87]] 80; and SEQ ID NO: [[69]] 62 and SEQ ID NO: [[83]] 76. - -

Please amend paragraph [0051] of the published application as follows:

- - Another embodiment of the present invention provides a molecule comprising V<sub>H</sub> and V<sub>L</sub> domains of amino acid sequences having SEQ ID NO: [[111]] 104 and [[100]] 103, which has specific affinity for FGFR1 and which blocks ligand-dependent activation of FGFR1, and the corresponding isolated nucleic acid molecules comprising polynucleotide sequences having SEQ ID NO: [[82]] 75 and SEQ ID NO: [[73]] 66. - -

Please amend paragraph [0093] of the published application as follows:

- - FIG. 28 is an example of a Fab expression vector, having SEQ ID NO: [[53]] 52, for use in accordance with the present invention. - -

Please amend paragraph [0094] of the published application as follows:

- - FIG. 29 is an example of a phage display vector, having SEQ ID NO: [[54]] 53, for use in accordance with the present invention. - -

Please amend paragraph [0095] of the published application as follows:

- - FIG. 30 depicts the polynucleotide sequences of the V<sub>L</sub> and V<sub>H</sub> of MSPRO antibodies of the present invention SEQ ID NOS: [[61-91]] 54-84. - -

Please amend paragraph [0108] of the published application as follows:

- - The polypeptide sequence of the V<sub>H</sub> and V<sub>L</sub> domains of the currently preferred embodiments of the present invention are presented below. **FIG. 30** provides the polynucleotide sequences of the preferred embodiments of the invention.

---

MS-Pro-2-VL (SEQ ID NO: [[92]]85)

---

1 DIELTQPPSV SVAPGQTARI SCSGDALGDK YASWYQQKPG QAPVLVIYDD  
51 SDRPSGIPER FSGSNSGNTA TLTISGTQAE DEADYYCQSY DYSADYVFGG  
101 GTKLTVLGQ

---

--

Please amend paragraph [0109] of the published application as follows:

- - corresponding to polynucleotide sequence having SEQ ID NO: [[74]] 67

---

MS-Pro-11-VL (SEQ ID NO: [[93]]86)

---

1 DIALTQPASV SGSPGQSITI SCTGTSSDVG GYNYVSWYQQ HPGKAPKLMI  
51 YDVSNRPSGV SNRFSGSKSG NTASLTISGL QAEDEADYYC QSHHFYEVFG  
101 GGTKLTVLGQ

---

--

Please amend paragraph [0110] of the published application as follows:

- - corresponding to polynucleotide sequence having SEQ ID NO: [[70]] 63

---

MS-PRO-12-VL (SEQ ID NO: [[94]]87)

---

1 DIELTQPPSV SVAPGQTARI SCSGDALGDK YASWYQQKPG QAPVLVIYDD  
51 SDRPSGIPER FSGSNSGNTA TLTISGTQAE DEADYYCQSY DFDFAVFGGG  
101 TKLTVLGQ

---

--

Please amend paragraph [0111] of the published application as follows:

- - corresponding to polynucleotide sequence having SEQ ID NO: [[77]] 68

---

MS-Pro-21-VL (SEQ ID NO: [[95]]88)

---

1 DIVMTQSPDS LAVSLGERAT INCRSSQSVL YSSNNKNYLA WYQQKPGQPP  
51 KLLIYWASTR ESGVPDRFSG SSGGTDFTLT ISSLQAEDVA VYYCQQYDSI  
101 PYTFGQGTKV EIKRT

---

--

Please amend paragraph [0112] of the published application as follows:

- - corresponding to polynucleotide sequence having SEQ ID NO: [[67]] 60

MS-Pro-24-VL (SEQ ID NO: [[96]]89)

1 DIVLTQSPAT LSLSPGERAT LSCRASQSVS SSYLAWYQQK PGQAPRLLIY  
51 GASSRATGVP ARFSGSGSGT DFTLTISSE PEDFATYYCQ QMSNYPDTFG  
101 QGTKVEIKRT

--

Please amend paragraph [0113] of the published application as follows:

- - corresponding to polynucleotide sequence having SEQ ID NO: [[64]] 57

MS-Pro-26-VL (SEQ ID NO: [[97]]90)

1 DIALTQPASV SGSPGQSITI SCTGTSSDVG GYNYVSWYQQ HPGKAPKLM 51  
YDVSNRPSGV SNRFSGSKSG NTASLTISGL QAEDEADYYC QSYDNNSDVV 101  
EGGGTKLTVL GQ

--

Please amend paragraph [0114] of the published application as follows:

- - corresponding to polynucleotide sequence having SEQ ID NO: [[71]] 64

MS-Pro-28-VL (SEQ ID NO: [[98]]91)

1 DIQMTQSPSS LSASVGDRVT ITCRASQGIS SYLAWYQQK GKAPKLLIYA  
51 ASSLQSGVPS RFSGSGSGTD FTLTISLQPEDFAVYYCFQ YGSIPPTFGQ  
101 GGTKVEIKRT

--

Please amend paragraph [0115] of the published application as follows:

- - corresponding to polynucleotide sequence having SEQ ID NO: [[62]] 55

MS-Pro-29-VL (SEQ ID NO: [[99]]92)

1 DIVLTQSPAT LSLSPGERAT LSCRASQSVS SSYLAWYQQK PGQAPRLLIY  
51 GASSRATGVP ARFSGSGSGT DFTLTISSE PEDFATYYCQ QTNNAPVTFG  
101 QGTKVEIKRT

--

Please amend paragraph [0116] of the published application as follows:

- - corresponding to polynucleotide sequence having SEQ ID NO: [[65]] 58

MS-Pro-54-VL (SEQ ID NO: [[100]]93)

1 DIELTQPPSV SVAPGQTARI SCSGDALGDK YASWYQQKPG QAPVLVIYDD  
51 SDRPSGIPER FSGSNSGNTA TLTISGTQAE DEADYYCQSY DYFKLVFGGG  
101 TKLTVLGQ

--

Please amend paragraph [0117] of the published application as follows:

- - corresponding to polynucleotide sequence having SEQ ID NO: [[73]] 66

MS-Pro-55-VL (SEQ ID NO: [[101]]94)

1 DIALTQPASV SGSPGQSITI SCTGTSSDVG GYNYVSWYQQ HPGKAPKLM I  
51 YDVSNRPSGV SNRFSGSKSG NTASLTISGL QAEDEADYYC QSYDMYNYIV  
101 FGGGTKLTVL GQ

--

Please amend paragraph [0118] of the published application as follows:

- - corresponding to polynucleotide sequence having SEQ ID NO: [[69]] 62

MS-Pro-59-VL (SEQ ID NO: [[102]]95)

1 DIELTQPPSV SVAPGQTARI SCSGDALGDK YASWYQQKPG QAPVLVIYDD  
51 SDRPSGIPER FSGSNSGNTA TLTISGTQAE DEADYYCQSY DGPDLWVFGG  
101 GTKLTVLGQ

--

Please amend paragraph [0119] of the published application as follows:

- - corresponding to polynucleotide sequence having SEQ ID NO: [[76]] 69

MS-Pro-2-VH (SEQ ID NO: [[103]]96)

1 QVQLVQSGAE VKKPGASVKV SCKASGYTFT SYMHWRQA PGQGLEWMGW 51  
INPNSGGTNY AQKFQGRVTM TRDTSISTAY MELSSLRSED TAVYYCARDF  
101 LGYEFDYWGQ GTLVTVSS

--

Please amend paragraph [0120] of the published application as follows:

- - corresponding to polynucleotide sequence having SEQ ID NO: [[84]] 77

MS-Pro-11-VH (SEQ ID NO: [[104]]97)

1 QVQLVQSGAE VKKPGASVKV SCKASGYTFT SYMHWRQA PGQGLEWMGW 51  
INPNSGGTNY AQKFQGRVTM TRDTSISTAY MELSSLRSED TAVYYCARYY  
101 GSSLYHYVFG GFIDYWGQGT LVTVSS

--

Please amend paragraph [0121] of the published application as follows:

- - corresponding to polynucleotide sequence having SEQ ID NO: [[85]] 78

MS-Pro-12-VH (SEQ ID NO: [[105]]98)

1 QVQLKESGPA LVKPTQTLT TCTFSGFSLT TSGVGVGWIR QPPGKALEWL  
51 ALIDWDDDKY YSTSLKTRLT ISKDTSKNQV VLTMTNMDPV DTATYYCARY  
101 HSWYEMGYYG STVGYMFDYW GQGT LVTVSS

--

Please amend paragraph [0122] of the published application as follows:

- - corresponding to polynucleotide sequence having SEQ ID NO: [[89]] 82

MS-Pro-21-VH (SEQ ID NO: [[106]]99)

1 QVQLVQSGAE VKKPGSSVKV SCKASGGTFS SYAISWRQA PGQGLEWMGG  
51 IPIFGTANY AQKFQGRVTI TADESTSTAY MELSSLRSED TAVYYCARDN  
101 WFKPFSDVWG QGT LVTVSS

--

Please amend paragraph [0123] of the published application as follows:

- - corresponding to polynucleotide sequence having SEQ ID NO: [[78]] 71

MS-Pro-24-VH (SEQ ID NO: [[107]]100)

1 QVQLVQSGAE VKKPGSSVKV SCKASGGTFS SYAISWRQA PGQGLEWMGG  
51 IPIFGTANY AQKFQGRVTI TADESTSTAY MELSSLRSED TAVYYCARVN  
101 HWTYTFDYWG QGT LVTVSS

--

Please amend paragraph [0124] of the published application as follows:

- - corresponding to polynucleotide sequence having SEQ ID NO: [[79]] 72

MS-Pro-26-VH (SEQ ID NO: [[108]]101)

1 QVQLVQSGAE VKKPGASVKV SCKASGYTFT SYMHWRQA PGQGLEWMGW 51  
INPNSGGTNY AQKFQGRVTM TRDTSISTAY MELSSLRSED TAVYYCARGY  
101 WYAYFTYINY GYFDNWGQGT LVTVSS

--

Please amend paragraph [0125] of the published application as follows:

- - corresponding to polynucleotide sequence having SEQ ID NO: [[86]] 79

MS-Pro-28-VH (SEQ ID NO: [[109]]102)

1 QVQLVQSGAE VKKPGSSVKV SCKASGGTFS SYAISWRQA PGQGLEWMGG  
51 IIPFGTANY AQKFQGRVTI TADESTSTAY MELSSLRSED TAVYYCARGG  
101 GWVSHGYYYL FDLWGQGT LV TVSS

--

Please amend paragraph [0126] of the published application as follows:

- - corresponding to polynucleotide sequence having SEQ ID NO: [[80]] 73

MS-Pro-29-VH (SEQ ID NO: [[110]]103)

1 QVQLVQSGAE VKKPGASVKV SCKASGYTFT SYMHWRQA PGQGLEWMGW 51  
INPNSGGTNY AQKFQGRVTM TRDTSISTAY MELSSLRSED TAVYYCARTW  
101 QYSYFYLDG GYYFDIWGQG TLVTVSS

--

Please amend paragraph [0127] of the published application as follows:

- - corresponding to polynucleotide sequence having SEQ ID NO: [[87]] 80

MS-Pro-54-VH (SEQ ID NO: [[111]]104)

1 QVQLVQSGAE VKKPGASVKV SCKASGYTFT SYMHWRQA PGQGLEWMGW 51  
INPNSGGTNY AQKFQGRVTM TRDTSISTAY MELSSLRSED TAVYYCARNM  
101 AYTNYQYVNM PHFDYWGQGT LVTVSS

--

Please amend paragraph [0128] of the published application as follows:

- - corresponding to polynucleotide sequence having SEQ ID NO: [[82]] 75

MS-Pro-55-VH (SEQ ID NO: [[112]]105)

1 QVQLVQSGAE VKKPGASVKV SCKASGYTFT SYMHWRQA PGQGLEWMGW 51  
INPNSGGTNY AQKFQGRVTM TRDTSISTAY MELSSLRSED TAVYYCARSM  
101 NSTMYWYLRR VLFDHWGQGT LVTVSS

- -

Please amend paragraph [0129] of the published application as follows:

- - corresponding to polynucleotide sequence having SEQ ID NO: [[83]] 76

MS-Pro-59-VH (SEQ ID NO: [[113]]106)

1 QVQLQQSGPG LVKPSQTLST TCAISGDSVS SNSAAWNWIR QSPGRGLEWL  
51 GRTYYRSKWY NDYAVSVKSR ITINPDTSKN QFSLQLNSVT PEDTAVYYCA  
101 RSYYPDFDYW GQGT LVTVSS

- -

Please amend paragraph [0130] of the published application as follows:

- - corresponding to polynucleotide sequence having SEQ ID NO: [[91]] 84 - -

Please amend paragraph [0182] of the published application as follows:

- - The invention also provides isolated nucleic acid molecule that hybridizes under high stringency conditions to polynucleotides having SEQ ID NO:30 through SEQ ID NO:51 and SEQ ID NOS: ~~62, 64-65, 67, 69-71, 73-76-78-80, 82-87, 89, 91~~ 55, 57-58, 60, 62-64, 66-69, 71-73, 75-80, 82, 84 or the complement thereof. As used herein, highly stringent conditions are those which are tolerant of up to about 5-20% sequence divergence, preferably about 5-10%. Without limitation, examples of highly stringent (-10° C. below the calculated T<sub>m</sub> of the hybrid) conditions use a wash solution of 0.1.times.SSC (standard saline citrate) and 0.5% SDS at the appropriate T<sub>i</sub> below the calculated T<sub>m</sub> of the hybrid. The ultimate stringency of the conditions is primarily due to the washing conditions, particularly if the hybridization conditions used are those which allow less stable hybrids to form along with stable hybrids. The wash conditions at higher stringency then remove the less stable hybrids. A common hybridization condition that can be used with the highly stringent to moderately stringent wash conditions described above is hybridization in a solution of 6xSSC (or 6xSSPE), 5x Denhardt's reagent, 0.5% SDS, 100 µg/ml



denatured, fragmented salmon sperm DNA at an appropriate incubation temperature  $T_i$ . See generally Sambrook et al. [1] (Molecular Cloning: A Laboratory Manual, 2d edition, Cold Spring Harbor Press (1989)) for suitable high stringency conditions. - -

Please amend paragraph [0232] of the published application as follows:

- - FIG. 30 displays the polynucleotide sequences of the specific  $V_L$  and  $V_H$  domains of MSPRO2 (SEQ ID NO: [74] 67 and [84] 77); MSPRO11 (SEQ ID NO: [70] 63 and [85] 78); MSPRO12 (SEQ ID NO: [75] 68 and [89] 82); MSPRO21 (SEQ ID NO: [67] 60 and [78] 71); MSPRO24 (SEQ ID NO: [64] 57 AND [79] 72); MSPRO26 (SEQ ID NO: [71] 64 AND [86] 79); MSPRO28 (SEQ ID NO: [62] 55 AND [80] 73); MSPRO29 (SEQ ID NO: [65] 58 AND [87] 80); MSPRO54 (SEQ ID NO: [73] 66 AND [82] 75); MSPRO55 (SEQ ID NO: [69] 62 AND [83] 76); and MSPRO59 (SEQ ID NO: [76] 69 AND [91] 84). The sequences include the framework domains 1-4 and the CDR domains 1-3. SEQ ID NO: [61] 54, SEQ ID NO: [63] 56, SEQ ID NO: [66] 59, SEQ ID NO: [68] 61, and SEQ ID NO: [73] 65 denote herein the polynucleotide sequences of the parent  $V_L$  (kappa or lambda) strands. SEQ ID NO: [77] 70, SEQ ID NO: [81] 74, SEQ ID NO: [88] 81 and SEQ ID NO: [90] 83 denote herein the polynucleotide sequences of the  $V_H$  parent strands. - -

Please replace TABLE 1F of the published application as follows:

<u>Peptide pairs</u> fragment				
antibody #	V heavy chain CDR3	V light chain CDR3	V heavy chain	V light chain
MSPRO2	SEQ ID NO: 8	SEQ ID NO: 9	SEQ ID NO: 96	SEQ ID NO: 85
MSPRO12	SEQ ID NO: 12	SEQ ID NO: 13	SEQ ID NO: 98	SEQ ID NO: 87
MSPRO59	SEQ ID NO: 24	SEQ ID NO: 25	SEQ ID NO: 106	SEQ ID NO: 95
MSPRO11	SEQ ID NO: 10	SEQ ID NO: 11	SEQ ID NO: 97	SEQ ID NO: 86
MSPRO21	SEQ ID NO: 14	SEQ ID NO: 15	SEQ ID NO: 99	SEQ ID NO: 88
MSPRO24	SEQ ID NO: 16	SEQ ID NO: 17	SEQ ID NO: 100	SEQ ID NO: 89
MSPRO26	SEQ ID NO: 18	SEQ ID NO: 19	SEQ ID NO: 101	SEQ ID NO: 90
MSPRO28	SEQ ID NO: 26	SEQ ID NO: 27	SEQ ID NO: 102	SEQ ID NO: 91
MSPRO29	SEQ ID NO: 20	SEQ ID NO: 21	SEQ ID NO: 103	SEQ ID NO: 92
MSPRO54	SEQ ID NO: 22	SEQ ID NO: 23	SEQ ID NO: 104	SEQ ID NO: 93
MSPRO55	SEQ ID NO: 28	SEQ ID NO: 29	SEQ ID NO: 105	SEQ ID NO: 94

Please replace TABLE 1G of the published application as follows:

<u>Nucleotide pairs</u> fragment				
antibody #	V heavy chain CDR3	V light chain CDR3	V heavy chain	V light chain
MSPRO2	SEQ ID NO: 30	SEQ ID NO: 31	SEQ ID NO: 77	SEQ ID NO: 67
MSPRO12	SEQ ID NO: 34	SEQ ID NO: 35	SEQ ID NO: 82	SEQ ID NO: 68
MSPRO59	SEQ ID NO: 50	SEQ ID NO: 51	SEQ ID NO: 84	SEQ ID NO: 69
MSPRO11	SEQ ID NO: 32	SEQ ID NO: 33	SEQ ID NO: 78	SEQ ID NO: 63
MSPRO21	SEQ ID NO: 36	SEQ ID NO: 37	SEQ ID NO: 71	SEQ ID NO: 60
MSPRO24	SEQ ID NO: 38	SEQ ID NO: 39	SEQ ID NO: 72	SEQ ID NO: 57
MSPRO26	SEQ ID NO: 40	SEQ ID NO: 41	SEQ ID NO: 79	SEQ ID NO: 64
MSPRO28	SEQ ID NO: 42	SEQ ID NO: 43	SEQ ID NO: 73	SEQ ID NO: 55
MSPRO29	SEQ ID NO: 44	SEQ ID NO: 45	SEQ ID NO: 80	SEQ ID NO: 58
MSPRO54	SEQ ID NO: 46	SEQ ID NO: 47	SEQ ID NO: 75	SEQ ID NO: 66
MSPRO55	SEQ ID NO: 48	SEQ ID NO: 49	SEQ ID NO: 76	SEQ ID NO: 62